Citations 1
NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM).
Anderson, S. Keith , Anastasiadis, P, Tran, David , Jeyapalan, Suriya, Anderson, Daniel M. , Buckner, Jan C. , Schiff, David , Galanis, Evanthia , Anastasiadis, Panagiotis, Tran, David D. , Kaufmann, Timothy J. , Giannini, Caterina
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2004-2004
